دورية أكاديمية
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
| العنوان: | Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study |
|---|---|
| المؤلفون: | Tolaney, Sara M., Beeram, Muralidhar, Beck, J. Thaddeus, Conlin, Alison, Dees, E. Claire, Puhalla, Shannon L., Rexer, Brent N., Burris, Howard A., Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N., Manuel, Allison M., Lithio, Andrew, Price, Gregory L., Chapman, Sonya C., Litchfield, Lacey M., Goetz, Matthew P. |
| المصدر: | Frontiers in Oncology, 11 |
| سنة النشر: | 2022 |
| المجموعة: | Carolina Digital Repository (UNC - University of North Carolina) |
| مصطلحات موضوعية: | CDK4, endocrine therapy, CDK6, abemaciclib, metastatic breast cancer |
| الوصف: | Background Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhibitor or fulvestrant in patients with advanced or metastatic breast cancer. This Phase 1b study evaluated the safety and tolerability, pharmacokinetics, and antitumor activity of abemaciclib in combination with endocrine therapy for metastatic breast cancer (MBC), including aromatase inhibitors (letrozole, anastrozole, or exemestane) or tamoxifen. Patients and Methods Women ≥18 years old with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) MBC were eligible for enrollment. Eligibility included measurable disease or non-measurable but evaluable bone disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, Eastern Cooperative Oncology Group performance status 0–1, and no prior chemotherapy for metastatic disease. Adverse events were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 and tumor response were assessed by RECIST v1.1. Results Sixty-seven patients were enrolled and received abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20), anastrozole (Part B, n=16), tamoxifen (Part C, n=16), or exemestane (Part D, n=15). The most common treatment-emergent adverse events (TEAE) were diarrhea, fatigue, nausea, and abdominal pain. Grade 4 TEAEs were reported in five patients (one each with hyperglycemia, hypertension, neutropenia, procedural hemorrhage, and sepsis). There was no effect of abemaciclib or endocrine therapy on the pharmacokinetics of any combination study drug. Across all treated patients, the median progression-free survival was 25.4 months (95% confidence interval: 18.0, 35.8). The objective response rate was 38.9% in 36 patients with measurable disease. Conclusions Abemaciclib in ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.17615/pbnq-vs11Test; https://cdr.lib.unc.edu/downloads/5m60r2805?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/5m60r2805Test |
| DOI: | 10.17615/pbnq-vs11 |
| الإتاحة: | https://doi.org/10.17615/pbnq-vs11Test https://cdr.lib.unc.edu/downloads/5m60r2805?file=thumbnailTest https://cdr.lib.unc.edu/downloads/5m60r2805Test |
| حقوق: | http://rightsstatements.org/vocab/InC/1.0Test/ |
| رقم الانضمام: | edsbas.A2B1D9A9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17615/pbnq-vs11 |
|---|